FDA clears Medicrea’s 3D-printed interbody devices

Medicrea's IB3D line allows surgeons to design interbody devices for individual patients.

Medicrea scored an FDA OK for its 3D-printed titanium interbody devices for spine surgery.

The IB3D suite of devices features the company’s surgeon-adaptive technology, dubbed AdapTEK, which allows surgeons to design interbody devices according to individual specifications, the company said in a statement. Medicrea then creates the implants at its in-house additive manufacturing facilities.

With the technology, surgeons are able to customize footprints, lordotic angles, heights, lateral windows and endplate surface structure, Medicrea said.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“With the FDA clearance of our 3D-printed Titanium interbodies, we are able to approach a large segment of the spine market, where we were not previously present, with an adaptive range of implants delivered according to the clinical preferences and practices of individual spine surgeons,” said Denys Sournac, Medicrea CEO, in the statement.

This will pave the way for future FDA clearances, which will allow the company to combine the IB3D line with its UNiD Adaptive Spine Intelligence platform, Sournac said.

Medicrea picked up $22.4 million in August 2016, which it pegged for the U.S. and international commercialization of its UNiD Patient-Specific Rods. FDA-cleared in 2014, the devices are customizable to each patient’s spinal alignment, which helps reduce the risk of spinal implant failure.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.